| MIS-C (n = 14) | Severe adult COVID-19 (n = 94) | P valuea | |
|---|---|---|---|
| Demographics | |||
| Females, n (%) | 7 (50) | 25 (27) | 0.0736 |
| Age, yr, median (IQR) | 10 (8.25–13.5) | 67 (58–74) | <0.0001 |
| Race/ethnicity | |||
| White/Caucasian, n (%) | 5 (35) | 90 (96) | <0.0001 |
| African/Black, n (%) | 4 (28) | 2 (2) | <0.0001 |
| Asian/Middle Eastern, n (%) | 3 (21) | 1 (1) | 0.0002 |
| Other, n (%) | 2 (14) | 1 (1) | 0.005 |
| BMI, median (IQR) | 17.8 (16.1–20.3) | 28.1 (25.8–31.6) | <0.0001 |
| Co-morbidities | |||
| Cardiovascular disease, n (%) | 0 (-) | 32 (36) | 0.0093 |
| Arterial hypertension, n (%) | 0 (-) | 34 (38) | 0.0066 |
| Diabetes mellitus, n (%) | 0 (-) | 28 (31) | 0.0177 |
| Chronic kidney disease, n (%) | 0 (-) | 13 (14) | 0.1379 |
| Chronic lung disease, n (%) | 0 (-) | 13 (14) | 0.1379 |
| Laboratory markers at inclusion | |||
| Hb, median (IQR), g/dl | 10.5 (9.9–11.2) | 13.3 (12.3–14.3) | <0.0001 |
| WBC, median (IQR), × 109/liter | 7.1 (5.7–10.7) | 7 (5.4–9.3) | 0.7004 |
| Lymphocytes, median (IQR), × 109/liter | 0.8 (0.6–1.1) | 0.6 (0.5–0.8) | 0.0766 |
| Eosinophils, median (IQR), × 109/liter | 0.1 (0–0.1) | 0 (0–0) | <0.0001 |
| Platelets, median (IQR), × 109/liter | 194.5 (172.3–229.8) | 218 (155.5–291.5) | 0.4366 |
| Creatinine, median (IQR), mg/dl | 0.6 (0.5–0.7) | 0.9 (0.8–1.1) | <0.0001 |
| Urea, median (IQR), mg/dl | 27 (17.7–37.8) | 28 (22–36) | 0.5339 |
| AST, median (IQR), U/liter | 33 (24–44) | 54 (38–76) | 0.0021 |
| ALT, median (IQR), U/liter | 38 (20–42) | 44 (30–63.5) | 0.1155 |
| GGT, median (IQR), U/liter | 47 (36–59) | 54.5 (28.8–101.5) | 0.2207 |
| Ferritin, median (IQR), µg/liter | 507 (285–736) | 1,704 (1,169–2,744.5) | <0.0001 |
| Fibrinogen, median (IQR), mg/dl | 523 (425–663.5) | 634 (571–728) | 0.0567 |
| D-dimer, median (IQR), ng/ml | 2,555 (2,002.5–4,855) | 1,100 (722.5–1,486.8) | 0.0006 |
| CRP, median (IQR), mg/liter | 286.4 (187.275–376.125) | 130.9 (86–190.7) | <0.0001 |
| MIS-C ( | Severe adult COVID-19 ( | P value | |
|---|---|---|---|
| Females, | 7 (50) | 25 (27) | 0.0736 |
| Age, yr, median (IQR) | 10 (8.25–13.5) | 67 (58–74) | |
| White/Caucasian, | 5 (35) | 90 (96) | |
| African/Black, | 4 (28) | 2 (2) | |
| Asian/Middle Eastern, | 3 (21) | 1 (1) | |
| Other, | 2 (14) | 1 (1) | |
| BMI, median (IQR) | 17.8 (16.1–20.3) | 28.1 (25.8–31.6) | |
| Cardiovascular disease, | 0 (-) | 32 (36) | |
| Arterial hypertension, | 0 (-) | 34 (38) | |
| Diabetes mellitus, | 0 (-) | 28 (31) | |
| Chronic kidney disease, | 0 (-) | 13 (14) | 0.1379 |
| Chronic lung disease, | 0 (-) | 13 (14) | 0.1379 |
| Hb, median (IQR), g/dl | 10.5 (9.9–11.2) | 13.3 (12.3–14.3) | |
| WBC, median (IQR), × 109/liter | 7.1 (5.7–10.7) | 7 (5.4–9.3) | 0.7004 |
| Lymphocytes, median (IQR), × 109/liter | 0.8 (0.6–1.1) | 0.6 (0.5–0.8) | 0.0766 |
| Eosinophils, median (IQR), × 109/liter | 0.1 (0–0.1) | 0 (0–0) | |
| Platelets, median (IQR), × 109/liter | 194.5 (172.3–229.8) | 218 (155.5–291.5) | 0.4366 |
| Creatinine, median (IQR), mg/dl | 0.6 (0.5–0.7) | 0.9 (0.8–1.1) | |
| Urea, median (IQR), mg/dl | 27 (17.7–37.8) | 28 (22–36) | 0.5339 |
| AST, median (IQR), U/liter | 33 (24–44) | 54 (38–76) | |
| ALT, median (IQR), U/liter | 38 (20–42) | 44 (30–63.5) | 0.1155 |
| GGT, median (IQR), U/liter | 47 (36–59) | 54.5 (28.8–101.5) | 0.2207 |
| Ferritin, median (IQR), µg/liter | 507 (285–736) | 1,704 (1,169–2,744.5) | |
| Fibrinogen, median (IQR), mg/dl | 523 (425–663.5) | 634 (571–728) | 0.0567 |
| D-dimer, median (IQR), ng/ml | 2,555 (2,002.5–4,855) | 1,100 (722.5–1,486.8) | |
| CRP, median (IQR), mg/liter | 286.4 (187.275–376.125) | 130.9 (86–190.7) | |
Bold and italic text indicates that P values are <0.05 and are considered significant. BMI, body mass index; Hb, hemoglobin.
Chi-square test (two-sided) for categorical variables, Mann–Whitney U for continuous variables, tested between adult COVID-19 and MIS-C.
As a benefit of your subscription, you can share temporary access to restricted articles.
Each link will stop working after 30 days or 10 uses. You may create up to 10 links in a 30 day period.
Please sign in to your personal account to gift article access.
As a benefit of your subscription, you can share temporary access to restricted articles.
Each link will stop working after 30 days or 10 uses. You may create up to 10 links in a 30 day period.
Gift articles remaining: --
Each link will stop working after 30 days or 10 uses. You may create up to 10 links in a 30 day period.
Gift articles remaining: --
As a benefit of your subscription, you can share temporary access to restricted articles.
Each link will stop working after 30 days or 10 uses.
You have reached the limit of 10 links within a 30 day period.
Sharing content requires targeting cookies to be enabled. Please update your cookie preferences to use this feature.